Biotech Values

[BTH]

That is why multi-kinase inhibitors can have broader usage and be more effective in the longer run.

WRONG.

Combination therapies, combining single-target agents at high potency with both combo drugs, will prove MUCH more effective (as noted by many clinicians and oncologists) than using an "all comer" multi-targeted kinase drug. You simply cannot get massive potency with a multi-targeted kinase that you would with a single-agent because it will just increase the toxicity of the drug.

I'm not the one embarrassed. You should be.